Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
10:20am, Wednesday, 06'th Aug 2025
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advised
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeoGenomics, Inc. - NEO
06:45pm, Thursday, 31'st Jul 2025
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ: NEO). Such investors are advise
Down 29.2% in 4 Weeks, Here's Why NeoGenomics (NEO) Looks Ripe for a Turnaround
10:55am, Wednesday, 30'th Jul 2025
NeoGenomics (NEO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimate
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
07:05am, Wednesday, 30'th Jul 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company's PanTracer portfolio.
NeoGenomics, Inc. (NEO) Q2 2025 Earnings Call Transcript
04:54pm, Tuesday, 29'th Jul 2025
NeoGenomics, Inc. (NASDAQ:NEO ) Q2 2025 Earnings Conference Call July 29, 2025 8:30 AM ET Company Participants Anthony P. Zook - CEO & Director Jeffrey S.
NeoGenomics (NEO) Meets Q2 Earnings Estimates
09:16am, Tuesday, 29'th Jul 2025
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.03 per share a year ago.
NeoGenomics Reports Second Quarter 2025 Results
07:05am, Tuesday, 29'th Jul 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its second-quarter results for the period ended June 30, 2025.
NEO Battery Materials Receives Notice of Allowance for Patents on Silicon Battery for Drone and Defence-Tech Applications
09:22am, Wednesday, 23'rd Jul 2025
TORONTO, July 23, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-ru
NEO Battery Materials Closes Final Tranche of Oversubscribed Private Placement
04:00pm, Friday, 18'th Jul 2025
TORONTO, July 18, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-ru
NEO Battery Appoints Battery Gigafactory Production Veteran, Seok Joung Youn, as Head of Manufacturing & Facility Operations
09:45am, Wednesday, 16'th Jul 2025
TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
04:07pm, Monday, 07'th Jul 2025
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ: NEO). Such investors are advised to cont
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zeo Energy Corp. - ZEO
10:00am, Wednesday, 02'nd Jul 2025
NEW YORK , July 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zeo Energy Corp. ("Zeo" or the "Company") (NASDAQ: NEO). Such investors are advised to cont
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
07:05am, Tuesday, 01'st Jul 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025.
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
07:05am, Monday, 30'th Jun 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launched PanTracer™ Tissue, a next-generation solid tumor profiling assay, with the option to add HRD testing.
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
07:05am, Tuesday, 24'th Jun 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025.
